Antonis C Antoniou

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
  2. ncbi Exploring the link between MORF4L1 and risk of breast cancer
    Griselda Martrat
    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
    Breast Cancer Res 13:R40. 2011
  3. ncbi Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
    Logan C Walker
    Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 12:R102. 2010
  4. ncbi The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Amanda B Spurdle
    Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 7:R176-83. 2005
  5. ncbi Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit, University of Cambridge, Cambridge, UK
    Hum Mol Genet 18:4442-56. 2009
  6. ncbi Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK
    Cancer Epidemiol Biomarkers Prev 18:601-10. 2009
  7. ncbi Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    J Med Genet 45:425-31. 2008
  8. ncbi Models of genetic susceptibility to breast cancer
    A C Antoniou
    Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
    Oncogene 25:5898-905. 2006
  9. ncbi Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    CR UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, Worts Causeway, University of Cambridge, Cambridge, CB1 8RN, UK
    Breast Cancer Res 8:R72. 2006
  10. ncbi Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    Am J Hum Genet 82:937-48. 2008

Detail Information

Publications49

  1. ncbi Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
    ..2)...
  2. ncbi Exploring the link between MORF4L1 and risk of breast cancer
    Griselda Martrat
    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
    Breast Cancer Res 13:R40. 2011
    ..To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens...
  3. ncbi Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
    Logan C Walker
    Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 12:R102. 2010
    ..In this study, we evaluated 24 SNPs tagged to 14 candidate genes derived through a novel approach that analysed gene expression differences to prioritise candidate modifier genes for association studies...
  4. ncbi The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Amanda B Spurdle
    Queensland Institute of Medical Research, Brisbane, Australia
    Breast Cancer Res 7:R176-83. 2005
    ..Women with germline BRCA1 mutations who carry at least one AR allele with 28 or more repeats have been reported to have an earlier age at onset of breast cancer...
  5. ncbi Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit, University of Cambridge, Cambridge, UK
    Hum Mol Genet 18:4442-56. 2009
    ..There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not...
  6. ncbi Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK
    Cancer Epidemiol Biomarkers Prev 18:601-10. 2009
    ..However, their effect on ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has only been investigated in a small number of studies...
  7. ncbi Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    J Med Genet 45:425-31. 2008
    ..Several algorithms that predict the likelihood of carrying a BRCA1 or a BRCA2 mutation are currently used in clinical practice to identify such individuals...
  8. ncbi Models of genetic susceptibility to breast cancer
    A C Antoniou
    Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
    Oncogene 25:5898-905. 2006
    ..Such a model of susceptibility has implications for both risk prediction and for future gene identification studies...
  9. ncbi Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    CR UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, Worts Causeway, University of Cambridge, Cambridge, CB1 8RN, UK
    Breast Cancer Res 8:R72. 2006
    ..However, their effects among BRCA1 and BRCA2 mutation carriers is still under debate. We used retrospective data on BRCA1 and BRCA2 mutation carriers from the UK to assess the effects of parity-related variables on breast cancer risk...
  10. ncbi Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    Am J Hum Genet 82:937-48. 2008
    ....
  11. ncbi Risk prediction models for familial breast cancer
    Antonis C Antoniou
    1CR UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK
    Future Oncol 2:257-74. 2006
    ..The review concludes with a discussion of the ways in which risk models could be improved in the immediate- and long-term future...
  12. ncbi RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
    Am J Hum Genet 81:1186-200. 2007
    ..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers...
  13. ncbi BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
    Antonis C Antoniou
    Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Breast Cancer Res 8:R3. 2006
    ..We also used this data set to estimate the age-specific risks for breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers...
  14. ncbi Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction
    Antonis C Antoniou
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Cancer Res 70:9742-54. 2010
    ..Our findings indicated that these risk differences might be sufficient to influence the clinical management of mutation carriers...
  15. ncbi The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Br J Cancer 98:1457-66. 2008
    ..BOADICEA can be used to predict carrier probabilities and cancer risks to individuals with any family history, and has been implemented in a user-friendly Web-based program (http://www.srl.cam.ac.uk/genepi/boadicea/boadicea_home.html)...
  16. ncbi Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
    Hum Mol Genet 20:3304-21. 2011
    ..27 and 0.30, respectively). The identification of SNPs at 6q25.1 associated with breast cancer risk for BRCA1 mutation carriers will lead to a better understanding of the biology of tumour development in these women...
  17. ncbi Incorporating tumour pathology information into breast cancer risk prediction algorithms
    Nasim Mavaddat
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK
    Breast Cancer Res 12:R28. 2010
    ..In particular, oestrogen receptor (ER)-negative status, triple-negative (TN) status, and expression of basal markers are predictive of BRCA1 mutation carrier status...
  18. ncbi Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  19. ncbi A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Nat Genet 42:885-92. 2010
    ..80, 95% CI 0.74-0.87, P(trend) = 1.1 × 10⁻⁷..
  20. ncbi Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study
    A C Antoniou
    CRC Genetic Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 21:1-18. 2001
    ....
  21. ncbi Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
    Nasim Mavaddat
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
    Cancer Epidemiol Biomarkers Prev 21:134-47. 2012
    ..Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization...
  22. ncbi A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact
    Robert J Macinnis
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 35:549-56. 2011
    ..This approach can be applied to other diseases for which population-based family data and established risk variants exist...
  23. ncbi A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes
    Antonis C Antoniou
    Cancer Research-UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, United Kingdom
    Genet Epidemiol 29:1-11. 2005
    ..The power to detect associations is, however, reduced compared with an unweighted approach...
  24. ncbi Clinical software development for the Web: lessons learned from the BOADICEA project
    Alex P Cunningham
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
    BMC Med Inform Decis Mak 12:30. 2012
    ....
  25. ncbi Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations
    Daniel R Barnes
    Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 36:274-91. 2012
    ..These methods are illustrated by analyses of genetic modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers...
  26. ncbi Familial relative risks for breast cancer by pathological subtype: a population-based cohort study
    Nasim Mavaddat
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 12:R10. 2010
    ..The contribution of genetic variants associated with breast cancer susceptibility to the subtype-specific FRR is still unclear...
  27. ncbi Genetic susceptibility to breast cancer
    Nasim Mavaddat
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom
    Mol Oncol 4:174-91. 2010
    ....
  28. ncbi The BOADICEA model of genetic susceptibility to breast and ovarian cancer
    A C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, Worts Causeway, Cambridge CB1 8RN, UK
    Br J Cancer 91:1580-90. 2004
    ..We conclude that this model provides a rational basis for risk assessment in individuals with a FH of breast or ovarian cancer...
  29. ncbi A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge CB1 8RN, UK
    Br J Cancer 86:76-83. 2002
    ..The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families...
  30. ncbi The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing
    Paul D P Pharoah
    Department of Oncology, University of Cambridge, Cambridge, United Kingdom
    Clin Cancer Res 17:3742-50. 2011
    ..However, only one published article, analyzing fewer than 1,000 subjects in total, has examined this association...
  31. ncbi Polygenic inheritance of breast cancer: Implications for design of association studies
    Antonis C Antoniou
    Cancer Research UK, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Genet Epidemiol 25:190-202. 2003
    ..These results indicate that association studies based on cases with a strong family history, identified for example through cancer genetics clinics, may be substantially more efficient than population-based studies...
  32. ncbi Common genetic variants and cancer risk in Mendelian cancer syndromes
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, UK
    Curr Opin Genet Dev 20:299-307. 2010
    ....
  33. ncbi Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies
    Robert J Macinnis
    Cancer Research UK Genetic Epidemiology Unit, Strangeways Laboratory, University of Cambridge, Cambridge, UK
    Genet Epidemiol 34:42-50. 2010
    ....
  34. ncbi Two ATM variants and breast cancer risk
    Deborah Thompson
    Cancer Research United Kingdom Genetic Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
    Hum Mutat 25:594-5. 2005
    ..4258C>T variant increases breast cancer risk, and little evidence that c.1066-6T>G confers an elevated risk. Analysis of additional families will be necessary to define more precisely the risk, if any, associated with c.1066-6T>G...
  35. ncbi Polygenes, risk prediction, and targeted prevention of breast cancer
    Paul D P Pharoah
    Department of Oncology, University of Cambridge, United Kingdom
    N Engl J Med 358:2796-803. 2008
    ..New developments in the search for susceptibility alleles in complex disorders provide support for the possibility of a polygenic approach to the prevention and treatment of common diseases...
  36. ncbi Risk models for familial ovarian and breast cancer
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 18:173-90. 2000
    ..The high penetrance estimate for ovarian cancer, compared with other studies, suggests that modifying genetic or environmental factors may be important determinants of risk...
  37. ncbi The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes
    S A Gayther
    Department of Oncology, Cancer Research Campaign, Strangeways Research Laboratory, Cambridge, United Kingdom
    Am J Hum Genet 65:1021-9. 1999
    ..We discuss the implications for genetic testing and clinical management of familial ovarian cancer arising from the data presented in these studies...
  38. ncbi Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
    Ana Teresa Maia
    Cambridge Research Institute CRUK, Li Ka Shing Centre, Cancer Research UK, Robinson Way, Cambridge, CB2 0RE, UK
    Breast Cancer Res 14:R63. 2012
    ..We have previously reported that BRCA2 shows differential allelic expression and we hypothesize that the known variable penetrance of BRCA2 mutations might be associated with this mechanism...
  39. ncbi AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study
    Fergus J Couch
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007
    ..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers...
  40. ncbi An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
    Georgia Chenevix-Trench
    Queensland Institute for Medical Research, Brisbane, Australia
    Breast Cancer Res 9:104. 2007
    ....
  41. ncbi The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain
    Roger L Milne
    Unidad de Genotipación CEGEN and Grupo de Genética Humana, Programa de Genética del Cáncer Humano, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Cancer Res 14:2861-9. 2008
    ..We aimed to estimate these penetrances for women attending genetic counseling units in Spain...
  42. ncbi Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France
    Valerie Bonadona
    Department of Public Health, Cancer Centre Léon Bérard, Lyon, France
    Genes Chromosomes Cancer 43:404-13. 2005
    ..The clinical assessment of HBC risk that we have developed should help in the decision to perform genetic testing...
  43. ncbi The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Amanda B Spurdle
    The Queensland Institute of Medical Research, Brisbane, Australia
    Cancer Epidemiol Biomarkers Prev 15:76-9. 2006
    ..Given the large sample size, with more than adequate power to detect previously reported effects, we conclude that the AIB1 glutamine repeat does not substantially modify risk of breast cancer in BRCA1 and BRCA2 mutation carriers...
  44. ncbi Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study
    Jenny Chang-Claude
    Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 280 69120 Heidelberg, Germany
    Cancer Epidemiol Biomarkers Prev 16:740-6. 2007
    ..Early menarche and late menopause are important risk factors for breast cancer, but their effects on breast cancer risk in BRCA1 and BRCA2 carriers are unknown...
  45. ncbi Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Gillian Mitchell
    Translational Cancer Genetics Team, Institute of Cancer Research and Cancer Genetics Unit, Royal Marsden NHS Hospital, United Kingdom
    Cancer Res 66:1866-72. 2006
    ..Use of mammographic density could improve individual risk prediction in carriers...
  46. ncbi BRCA1 and BRCA2 cancer risks
    Antonis C Antoniou
    J Clin Oncol 24:3312-3; author reply 3313-4. 2006
  47. ncbi Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)
    Nadine Andrieu
    INSERM, Emi00 06, Service de Biostatistique, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    J Natl Cancer Inst 98:535-44. 2006
    ..Because mammary gland cells divide and differentiate during pregnancy, reproductive factors may influence breast cancer risk in BRCA1/2 mutation carriers differently than they do in noncarriers...
  48. ncbi Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group
    Nadine Andrieu
    , Paris, France
    J Clin Oncol 24:3361-6. 2006
    ..If confirmed, the results have important implications for the use of x-ray imaging in young BRCA1/2 carriers...
  49. ncbi Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group
    Richard M Brohet
    Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, The Netherlands
    J Clin Oncol 25:3831-6. 2007
    ..However, duration of use, especially before first full-term pregnancy, may be associated with an increasing risk of breast cancer among both BRCA1 and BRCA2 mutation carriers...